Dr. Andrew Chen This is Me

Education

 View all 19 references Web References

1. 1. BioWorld Today

   www.bioworld.com/servlet/com.a - [Cached]

   Published on: 4/11/2006   Last Visited: 4/11/2006

   Andrew Chen, a co-founder of SD Pharma, will continue to collaborate with Adventrx as a consultant. The merger would give Adventrx worldwide intellectual property rights to eight oncology and infectious disease product candidates, including ex-U.S. rights to SDP-012 (ANX-530, vinorelbine emulsion). Adventrx licensed U.S. development and marketing rights to the product from SD Pharma last October. Other candidates are based on a nano-emulsion technology, developed by Chen, for both soluble and insoluble parenteral drugs.

2. 2. ADVENTRX Signs Definitive Merger Agreement with SD Pharmaceuticals: Financial News - Yahoo! Finance

   biz.yahoo.com/prnews/060410/ny - [Cached]

   Published on: 4/10/2006   Last Visited: 4/10/2006

   SD Pharma co-founder, Andrew Chen, Ph.D., R.Ph, will continue to collaborate with ADVENTRX as a consultant.
   ...
   The nano-emulsion technology was developed by Dr. Andrew Chen and is designed to enable the delivery of vein irritating or difficult to dissolve drugs without excipient-induced adverse effects.
   ...
   "We plan to build on our 505(b)(2) regulatory experience and our familiarity with Dr. Chen's nano-emulsion technologies and to apply these skills to compounds with even larger market opportunities.

3. 3. Small Times: News about MEMS, Nanotechnology and Microsystems

   www.smalltimes.com/document_di - [Cached]

   Published on: 5/1/2006   Last Visited: 5/2/2006

   The nano-emulsion technology was developed by SD Pharma co-founder, Andrew Chen, Ph.D., Rh.P., in an effort to address limitations with current drug formulations, such as injection site reactions and hypersensitivity reactions.